Castle biosciences stock.

Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.

It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Stock ...All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...

Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...

Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,650 on 14 July 2023.440 units of CSTL stock worth $8,650 on 14 July 2023.Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...Following this news, Relmada’s stock price fell nearly 80% to close at $6.48 per share on October 13, 2022. ... Castle Biosciences, Inc. (NASDAQ: CSTL)Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: A patent application pending for Castle Biosciences. Kyle R. Covington. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other …

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.

Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MOn average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64.

May 30, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ... Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the …On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Apr 5, 2022 · AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ... All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Nov 16, 2023 · Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...

Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. ... Net loss for the third quarter, which includes non-cash stock-based compensation expense of $13.0 million, …Castle Biosciences (CSTL-0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...Castle Biosciences price target raised to $30 from $25 at Baird 07/25/23 Craig-Hallum Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal 07/07/23 KeyBanc Castle Biosciences stock up amid ADLT status for DecisionDx-SCC, says KeyBanc 07/07/23 Lake Street Lake Street says Castle …But note: Castle Biosciences may not be the best stock to buy.So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).. Please note, the ...2/28/2023, Q4 2022, ($0.91) ; 11/2/2022, Q3 2022, ($0.70) ; 8/8/2022, Q2 2022, ($0.58) ; newsletter. Get the Latest News and Ratings for CSTL and Related Stocks.Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86. During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35. The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a ...

In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...NASDAQ: CSTL + 19.38 -0.68 ( -3.39% ) Minimum 20 minutes delayed November 21, 2023 4:00 PM Overview Castle Biosciences is improving health through …David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...Castle Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CSTL updated stock price target summary.Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,642 on 14 July 2023.. The largest trade Kim's ever made was exercising 3,825 units of Castle Biosciences …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for …

Jun 15, 2023 · Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ... Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …7 Nis 2021 ... Product details ... Do you want to earn up to a 1117163% annual return on your money by two trades per day on Castle Biosciences Inc CSTL Stock?Instagram:https://instagram. how many stocks in the stock marketbest investment firmsgood brokers for day tradingmost expensive house in dubai At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. best value stocks right nowozempic and kidney disease Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you. ark7 review Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...